HOSPITAL UNIVERSITARIO RUBER

2013

1. Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel

   Anti-Cancer Drugs, Vol. 24, Núm. 10, pp. 1084-1092

2. Adjuvant bevacizumab: Positive data from a negative trial

   The Lancet Oncology

3. Anales de Pediatría: The past, the present and the future

   Anales de Pediatria, Vol. 79, Núm. 5, pp. 277-278

4. Bevacizumab in advanced breast cancer: A new model for the assessment of activity in non-first-line treatment regimens

   Anti-Cancer Drugs, Vol. 24, Núm. 9, pp. 975-979

5. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

   British Journal of Cancer, Vol. 108, Núm. 5, pp. 1052-1060

6. Bone metastases: Causes, consequences and therapeutic opportunities

   European Journal of Cancer, Supplement

7. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: A randomized, double-blind, placebo-controlled phase III study

   Oncologist, Vol. 18, Núm. 3, pp. 257-264

8. Circulating tumour cells and cell-free DNA as tools for managing breast cancer

   Nature Reviews Clinical Oncology, Vol. 10, Núm. 7, pp. 377-389

9. Clinical, biochemical, and neuroimaging findings predict long-term neurodevelopmental outcome in symptomatic congenital cytomegalovirus infection

   Journal of Pediatrics, Vol. 163, Núm. 3

10. Contribution of ADAMTS1 as a tumor suppressor gene in human breast carcinoma. Linking its tumor inhibitory properties to its proteolytic activity on nidogen-1 and nidogen-2

    International Journal of Cancer, Vol. 133, Núm. 10, pp. 2315-2324

11. Current situation: Lower genital tract pathology and colposcopy training in spanish gynecology and obstetrics residents

    Journal of Lower Genital Tract Disease, Vol. 17, Núm. 1, pp. 12-16

12. D. Torrejon, J. Cortes, D. Serpico, S. Di Cosimo à l'article de F. Vasseur et al.: KI67 chez les patientes jeunes présentant un cancer du sein. Gynecol Obstet Fertil 2013; 41(1):16-9

    Gynecologie Obstetrique et Fertilite

13. Dasatinib plus capecitabine for advanced breast cancer: Safety and efficacy in phase I study CA180004

    Clinical Cancer Research, Vol. 19, Núm. 7, pp. 1884-1893

14. Detección de protozoos parásitos entéricos, bacteriófagos de E. coli y organismos indicadores de contaminación en camarones comercializados en el estado Zulia

    Kasmera, Vol. 41, Núm. 1, pp. 16-26

15. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: The effect of Metoprolol in Cardioprotection during an Acute Myocardial Infarction (METOCARD-CNIC) Trial

    Circulation, Vol. 128, Núm. 14, pp. 1495-1503

16. Episodio aparentemente letal neonatal durante el «piel con piel». Tratamiento con hipotermia

    Anales de Pediatria, Vol. 79, Núm. 4, pp. 253-256

17. Exposure-response analysis of pertuzumab in HER2-positive metastatic breast cancer: Absence of effect on QTc prolongation and other ECG parameters

    Cancer Chemotherapy and Pharmacology, Vol. 72, Núm. 5, pp. 1133-1141

18. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: Pooled and subgroup analyses of data from 2447 patients

    Annals of Oncology, Vol. 24, Núm. 11, pp. 2773-2780

19. Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity

    Scientific Reports, Vol. 3

20. HER2-positive metastatic breast cancer: First-line treatment

    Handbook of HER2-Targeted Agents in Breast Cancer (Springer Healthcare), pp. 43-60